WO1998046585A1 - Inhibitors of cholesterol esterase - Google Patents
Inhibitors of cholesterol esterase Download PDFInfo
- Publication number
- WO1998046585A1 WO1998046585A1 PCT/US1998/007263 US9807263W WO9846585A1 WO 1998046585 A1 WO1998046585 A1 WO 1998046585A1 US 9807263 W US9807263 W US 9807263W WO 9846585 A1 WO9846585 A1 WO 9846585A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- present
- cholesterol
- compound
- inhibitors
- compounds
- Prior art date
Links
- 0 C[C@]1(CCCC2)[C@]2(C)*CCC1 Chemical compound C[C@]1(CCCC2)[C@]2(C)*CCC1 0.000 description 4
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D309/36—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
- C07D309/38—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms one oxygen atom in position 2 or 4, e.g. pyrones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- the present invention relates to inhibitors of cholesterol esterase.
- the inhibitors of the present invention provide a new approach to the treatment of hypercholesterolemia through limiting the bioavailability of dietary cholesterol.
- the present invention provides a compound comprising:
- R is a member of the group consisting of:
- n 0 to 8.
- R 2 , R relieve R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , and R l0 H, C,. 8 alkyl, C,. g cycloalkyl, C 2 , alkenyl, or C 2 _ 8 alkynyl.
- the present invention provides a compound
- R n is a member of the group consisting of:
- n 0 to 8.
- 9> and R 20 H, C,. g alkyl, C 3 . 8 cycloalkyl, C 2 . : alkenyl, or C 2 . 8 alkynyl.
- the present invention provides a compound comprising:
- Y, H or C
- R, ⁇ , R 22 , R 2 H, C
- Figure 1 illustrates one method for forming compounds of the present invention
- Figure 2 illustrates a second method for forming compounds of the present invention
- Figure 3 illustrates a third method for forming compounds of the present invention
- Figure 4 illustrates a fourth method for forming compounds of the present invention
- Figure 5 illustrates a fifth method for forming compounds of the present invention.
- Figure 6 is a graph showing the inhibition of cholesterol esterase by a compound of the present invention.
- C,. s alkyl refers to a straight or branched chain alkyl moiety having one ot eight carbon atoms including for example, methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, isobutyl, pentyl, dimethyl-propyl, hexyl, and octyl, and cognate terms (such as "C, 8 alkoxy") are to be construed accordingly.
- C, billing 5 alkyl refers to a straight or branched chain alkyl moiety having one to five carbon atoms (such as methyl or ethyl).
- C,. 8 cycloalkyl refers to a saturated alicyclic moiety having from 3 to 8 carbon atoms arranged in a ring and includes, for example, cyclopropyl, cyclobutyl, cyclopentyl, and cyclooctyl.
- C 2 . 8 alkenyl refers to a straight or branched chain alkyl moiety having one to eight carbon atoms and having in addition at least one double bond of either E or Z stereochemistry where applicable. This term would include, for example, vinyl, 1- propenyl, 1- and 2-butenyl and 2-methyl-2-propenyl.
- C 2 . 8 alkynyl refers to a straight or branched chain alkyl moiety having one to eight carbon atoms and having in addition at least one triple bond. This term would include, for example, propargyl, and 1- and 2-butynyl.
- Artherosclerotic heart disease is correlated to serum cholesterol levels. Therefore, a treatment which decreases the amount of dietary cholesterol absorbed from the intestine should also reduce a person's susceptibility to atherosclerotic heart disease.
- the compounds of the present invention act as cholesterol esterase (CE) inhibitors, that is they prevent CE from hydrolyzing dietary cholesterol esters in the intestines.
- CE cholesterol esterase
- the compounds of the present invention have structures which allow them to enter the active site of CE, a serine esterase, and bind covalently to certain residues. This results in a permanent inactivation of the enzyme.
- the compounds of the present invention combine structural features of known good inhibitors of serine esterases and the structural features of a known potent irreversible inhibitor of CE.
- Dietary cholesterol is comprised of free and esterified cholesterol, the ratio depending upon the dietary source. In diets rich in meats, up to 75% of cholesterol is esterified. Hydrolysis of cholesterol ester in the lumen of the small intestine is catalyzed by cholesterol esterase (CE) which liberates free cholesterol. Free cholesterol mixes with cholesterol contained in bile secretions to form the pool of cholesterol which is capable of being absorbed. Due to the low solubility of cholesterol, solubilization of cholesterol by bile salts into micelles is essential. In addition, transport proteins are required to deliver cholesterol from micelles to the enterocytes for absorption. CE provides both the hydrolytic activity for hydrolysis of cholesterol ester and the transport function for delivery of cholesterol from micelles to enterocytes.
- Esterification of cholesterol within the enterocyte also utilizes CE which can catalyze the reverse reaction under certain conditions.
- CE within the enterocyte is immunochemically related to pancreatic CE.
- the present invention's active site inhibitors of CE are effective in reducing the bioavailabilty of dietary cholesterol.
- pancreatic CE The catalytic mechanism of pancreatic CE resembles that of serine proteases such as trypsin and serine esterases such as acetylcholine esterase. Sequence comparisons indicate that SI 94, H435 and D79 comprise the active site triad of serine, histidine and aspartic acid in pancreatic CE, corresponding to S 195, H57 and D102 in trypsin. The importance of these residues in CE has been demonstrated by site directed mutagenesis studies by DiPersio et al. in "Site-directed mutagenesis of an essential histidine residue in pancreatic cholesterol esterase," J. Biol. Chem., 266, 4033-4036 (1991).
- 3-Benzyl-6-chloropyrone is a prototype haloenol lactone that has been developed as a suicide inhibitor of chymotrypsin, although it is not highly selective as described in Daniels et al. in "Haloenol lactones. Potent enzyme-activated irreversible inhibitors for ⁇ - chymotrypsin," J. Biol. Chem., 250, 15046-15053 (1983) (Suicide inhibitors, also called suicide substrates, require catalytic activation to a form that irreversibly modifies the enzyme.).
- the compounds of the present invention improve on existing haloeonol lactone suicide inhibitors by being selective for CE.
- One method for synthesizing compounds of the present invention is Scheme 1 illustrated in Figure 1.
- An appropriately substituted diethylmalonate sodium salt (1A) is heated with a c ⁇ -2-chloroacrylate (IB) to give a triester compound (1C).
- Saponification and decarboxylation of the triester compound (1 C) produces a substituted glutaconic acid (ID) which is often present as a mixture of the E and Z isomers.
- Cyclization is then performed using an acetyl halide cyclization agent (such as acetyl chloride or acetyl bromide) to give the 3-substituted 6-halopyrone (IE) and 5-substituted 6-halopyrone ( I F).
- IE 3-substituted 6-halopyrone
- I F 5-substituted 6-halopyrone
- the 3-substituted 6-halopyrone of the invention (I E) is then separated form the other isomer and purified using conventional column chromatography techniques.
- the method of scheme 1 is similar to a procedure described by Boulanger and Katzenellenbogen in "Structure Activity Study of 6-Substituted 2-Pyranones as Inactivators of -chymotrypsin" in J. Med. Chem., 29, 1 159-1 163 (1986).
- a second method for synthesizing compounds of the present invention is Scheme 2 illustrated in Figure 2.
- Halolactone compounds of the present invention (2G) are then produced by halolactonization of the acetylenic acid intermediate (2D) with an N-halosuccinimide (NXS; 2E) and potassium bicarbonate (2F).
- the N-halosuccinimide (2E) can be N-bromosuccinimide, N- chlorosuccinimide or N-iodosuccinimide.
- a third method for synthesizing compounds of the present invention is Scheme 3 illustrated in Figure 3.
- Halolactone compounds of the present invention (3G) are then produced by halolactonization of the acetylenic acid intermediate (3D) with an N-halosuccinimide (NXS; 3E) and potassium bicarbonate (3F).
- the N-halosuccinimide (3E) can be N-bromosuccinimide, N-chlorosuccinimide or N- iodosuccinimide.
- a fourth method for synthesizing compounds of the present invention is Scheme 4 illustrated in Figure 4.
- 2-(2-Oxopropyl)cyclohexanecarboxylic acid (4A) is reacted with a halogen X 2 (4B) to produce a halo keto acid intermediate (4C).
- X 2 can be chlorine, bromine or iodine.
- Pyridinium tribromide can be used as the source of bromine.
- Halolactone compounds of the present invention (4E) are then produced by halolactonization of the intermediate (4C) with trifluoroacetic acid anhydride (4D).
- a fifth method for synthesizing compounds of the present invention is Scheme 5 illustrated in Figure 5.
- 2-Acetylcyclohexanecarboxylic acid (5 A) is reacted with a halogen X 2 (5B) to produce a halo keto acid intermediate (5C).
- X 2 can be chlorine, bromine or iodine.
- Pyridinium tribromide can be used as the source of bromine.
- Halolactone compounds of the present invention (5E) are then produced by halolactonization of the intermediate (5C) with trifluoroacetic acid anhydride (5D).
- E isomers 2G and 3G The Z isomers of these compounds can be produced using a method similar to that described in Dai and Katzenellenbogen, "Stereoselective Z- and E- Bromo Enol Lactonization of Alkynoic Acids" in J. Org. Chem., 56, 6893-6896 (1991).
- treating the silver salt of compound 2D with a halogen X in acetonitrile can be used to provide the following Z isomer compound of the present invention 2H:
- treating the silver salts of compounds 3D, 4D, and 5D can be used to produce the following Z isomer compounds of the present invention 3H, 4H and 5H, respectively:
- the compounds of the present invention are potent inhibitors of CE.
- the compounds of the present invention are also highly selective for CE, unlike 3-substituted 6-chloropyrones such as 3-benzyl-6-chloropyrone where the 3-substituent includes an aromatic ring.
- the compounds of the present invention which have a saturated ring as part of the 3-substituent provide tremendous selectivity when compared to compounds where the 3- substituent includes an aromatic ring.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP54411598A JP2002512611A (en) | 1997-04-16 | 1998-04-15 | Cholesterol esterase inhibitor |
DE69819482T DE69819482T2 (en) | 1997-04-16 | 1998-04-15 | CHOLESTEROLESTERASE INHIBITORS |
AT98918098T ATE253565T1 (en) | 1997-04-16 | 1998-04-15 | CHOLESTEROLESTERASE INHIBITORS |
CA002284525A CA2284525A1 (en) | 1997-04-16 | 1998-04-15 | Inhibitors of cholesterol esterase |
EP98918098A EP0975617B1 (en) | 1997-04-16 | 1998-04-15 | Inhibitors of cholesterol esterase |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4198897P | 1997-04-16 | 1997-04-16 | |
US60/041,988 | 1997-04-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998046585A1 true WO1998046585A1 (en) | 1998-10-22 |
Family
ID=21919442
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/007263 WO1998046585A1 (en) | 1997-04-16 | 1998-04-15 | Inhibitors of cholesterol esterase |
Country Status (7)
Country | Link |
---|---|
US (3) | US5942631A (en) |
EP (1) | EP0975617B1 (en) |
JP (1) | JP2002512611A (en) |
AT (2) | ATE253565T1 (en) |
CA (1) | CA2284525A1 (en) |
DE (2) | DE69824901D1 (en) |
WO (1) | WO1998046585A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7115279B2 (en) | 2000-08-03 | 2006-10-03 | Curatolo William J | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
US20100324075A1 (en) * | 2007-12-21 | 2010-12-23 | University Of Cincinnati | Therapeutic use of carboxyl ester lipase inhibitors |
US9061796B2 (en) * | 2009-04-23 | 2015-06-23 | H.J. Heinz Company | Multi-function condiment container |
EP2844303B1 (en) | 2012-05-03 | 2021-09-15 | Beth Israel Deaconess Medical Center, Inc. | Lipids that increase insulin sensitivity and methods of using the same |
US10604473B2 (en) | 2013-03-15 | 2020-03-31 | Beth Israel Deaconess Medical Center, Inc. | Lipids that increase insulin sensitivity and methods of using the same |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4338122A (en) * | 1979-09-26 | 1982-07-06 | Union Carbide Corporation | Biocidal 2-aryl-1,3-cyclopentanedione compounds and alkali metal and ammonium salts thereof |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3056802A (en) * | 1960-10-04 | 1962-10-02 | Union Carbide Corp | Alpha-halo lactones |
US3227736A (en) * | 1962-10-31 | 1966-01-04 | Olin Mathieson | Production of alpha-fluorocarboxylic acids and esters |
US3346594A (en) * | 1965-08-25 | 1967-10-10 | Gen Aniline & Film Corp | Haloalkyl and polyhaloalkyl lactones |
GB2168696B (en) * | 1984-12-21 | 1989-01-11 | Boehringer Biochemia Srl | Fluoro coumarins as antilymphoedema agents |
US5025017A (en) * | 1989-09-28 | 1991-06-18 | E. R. Squibb & Sons, Inc. | Seco-mevinic acid derivatives useful as antihypercholesterolemic agents and new intermediates |
US5059696A (en) * | 1990-03-15 | 1991-10-22 | Merck & Co., Inc. | Processes and intermediates for the preparation of 5-oxygenated hmg-coa reductase inhibitors |
GB9100174D0 (en) * | 1991-01-04 | 1991-02-20 | British Bio Technology | Compounds |
WO1994012143A2 (en) * | 1992-11-18 | 1994-06-09 | Firmenich Sa | Use of furanones as scenting ingredients |
FR2741620B1 (en) * | 1995-11-28 | 1997-12-26 | Oreal | PROCESS FOR THE PREPARATION OF COMPOUNDS WITH A BETA-HYDROXY -DELTA-LACTONE GROUP ANALOGS OF (+) COMPACTIN AND (+) MEVINOLINE |
-
1998
- 1998-04-15 US US09/060,250 patent/US5942631A/en not_active Expired - Fee Related
- 1998-04-15 WO PCT/US1998/007263 patent/WO1998046585A1/en active IP Right Grant
- 1998-04-15 DE DE69824901T patent/DE69824901D1/en not_active Expired - Lifetime
- 1998-04-15 EP EP98918098A patent/EP0975617B1/en not_active Expired - Lifetime
- 1998-04-15 CA CA002284525A patent/CA2284525A1/en not_active Abandoned
- 1998-04-15 DE DE69819482T patent/DE69819482T2/en not_active Expired - Fee Related
- 1998-04-15 AT AT98918098T patent/ATE253565T1/en not_active IP Right Cessation
- 1998-04-15 AT AT03006153T patent/ATE270284T1/en not_active IP Right Cessation
- 1998-04-15 JP JP54411598A patent/JP2002512611A/en active Pending
-
1999
- 1999-04-15 US US09/291,990 patent/US6034255A/en not_active Expired - Fee Related
- 1999-12-16 US US09/464,194 patent/US6114545A/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4338122A (en) * | 1979-09-26 | 1982-07-06 | Union Carbide Corporation | Biocidal 2-aryl-1,3-cyclopentanedione compounds and alkali metal and ammonium salts thereof |
Non-Patent Citations (3)
Title |
---|
ARCADI A, ET AL.: "PALLADIUM-CATALYZED REACTION OF VINYL TRIFLATES AND VINYL/ARYL HALIDES WITH 4-ALKYNOIC ACIDS: REGIO- AND STEREOSELECTIVE SYNTHESISOF (E)-DELTA-VINYL/ARYL-GAMMA-METHYLENE-GAMMA-BUTYROLACTONES", THE JOURNAL OF ORGANIC CHEMISTRY, AMERICAN CHEMICAL SOCIETY ^ETC.|, vol. 52, 1 January 1992 (1992-01-01), pages 976 - 982, XP002912733, ISSN: 0022-3263, DOI: 10.1021/jo00029a035 * |
MORENO-MAFIAS M, RIBAS J, VIRGILI A: "PALLADIUM-CATALYZED C-ALKYLATIONS OF THE HIGHLY ACIDIC AND ENOLIC TRIACETIC ACID LACTONE. MECHANISM AND STEREOCHEMISTRY", THE JOURNAL OF ORGANIC CHEMISTRY, AMERICAN CHEMICAL SOCIETY ^ETC.|, vol. 53, 1 January 1988 (1988-01-01), pages 5328 - 5335, XP002912732, ISSN: 0022-3263, DOI: 10.1021/jo00257a023 * |
YAMAMOTO M: "CYCLISATION OF ACETYLENECARBOXYLIC ACID. SYNTHESIS OF GAMMA-METHYLENE- BUTYROLACTONES", JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS 1, ROYAL SOCIETY OF CHEMISTRY, GB, vol. 02, 1 January 1981 (1981-01-01), GB, pages 582 - 587, XP002912734, ISSN: 0300-922X, DOI: 10.1039/p19810000582 * |
Also Published As
Publication number | Publication date |
---|---|
EP0975617A1 (en) | 2000-02-02 |
US6034255A (en) | 2000-03-07 |
DE69824901D1 (en) | 2004-08-05 |
JP2002512611A (en) | 2002-04-23 |
ATE253565T1 (en) | 2003-11-15 |
DE69819482T2 (en) | 2004-08-26 |
ATE270284T1 (en) | 2004-07-15 |
US6114545A (en) | 2000-09-05 |
US5942631A (en) | 1999-08-24 |
DE69819482D1 (en) | 2003-12-11 |
EP0975617B1 (en) | 2003-11-05 |
EP0975617A4 (en) | 2000-09-13 |
CA2284525A1 (en) | 1998-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4863957A (en) | Novel HMG-CoA reductase inhibitors | |
IE903262A1 (en) | 4-Hydroxytetrahydropyran-2-ones and the corresponding dihydroxycarboxylic acid derivatives, salts and esters, process for their preparation, their use as pharmaceuticals, and pharmaceutical preparations and precursors | |
EP0975617B1 (en) | Inhibitors of cholesterol esterase | |
US20020123527A1 (en) | HIV integrase inhibitors | |
EP1323715B1 (en) | Inhibitors of cholesterol esterase | |
JP2004502684A (en) | Coumarin derivatives having COMT inhibitory activity | |
WO2014205380A1 (en) | Compounds and compounds for use in methods for treating diseases or conditions mediated by protein disulfide isomerase | |
JPH0468316B2 (en) | ||
US5034548A (en) | Steroid derivatives useful as hypocholesterolemics | |
Stalder et al. | Tetrahydrolipstatin: Degradation products produced by human carboxyl‐ester lipase | |
Uesato et al. | Antitumor promoting activities of 3-O-acyl-(−)-epigallocatechins | |
US5049578A (en) | 1-aroyl or 1-acyl-2-2pyrrolidinyl-3,5-dihydroxy alkanoic and alkenoic acids, salts, esters and lactones | |
US4609650A (en) | Double ester of 16β-ethylestran-17β-ol derivatives | |
US20110245285A1 (en) | Process for preparation of rosuvastatin acetonide calcium | |
RU2359954C2 (en) | Benzotropolone derivatives possessing anti hiv-activity, pharmaceutical composition; method of hiv-integrase inhibition | |
US4609673A (en) | Carboxylic acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing them | |
JPH07215992A (en) | 6-or 7-substituted androsra-1,4-diene derivative | |
JPH03173848A (en) | Mebinic acid derivative | |
US20100160670A1 (en) | Novel process for the preparation of chiral compounds derived from hexanoic acid esters and intermediates used in the synthesis of chiral-2-(bromomethyl)-2-ethylhexanoic acid | |
JPH0676361B2 (en) | Pharmaceutical composition for treating or preventing atherosclerosis | |
JP3231909B2 (en) | New production method and intermediate of 20-keto-21 (S) -hydroxysteroid compound | |
JP3491296B2 (en) | Optically active 1,5-disubstituted-2,4-O-isopropylidene-2,4-dihydroxypentane and process for producing the same | |
EP0392015B1 (en) | Novel derivatives of physiologically active substance ml-236b and process for their preparation | |
Fukushima et al. | Synthesis of α-Methylene-γ-lactone Structure by Cyclization of ω-Formylallylsilane in Water | |
JP3002484B2 (en) | 4-hydroxy-6-octahydronaphthylethyltetrahydropyran-2-one derivative |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1998918098 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2284525 Country of ref document: CA Ref country code: CA Ref document number: 2284525 Kind code of ref document: A Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 1998918098 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 1998544115 Format of ref document f/p: F |
|
WWG | Wipo information: grant in national office |
Ref document number: 1998918098 Country of ref document: EP |